CSI Market
Sign In | Register

Nervgen Pharma (NGEN) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access NGEN Annual Cash Flow →
This cash flow overview for Nervgen Pharma spans from Dec 31 2024 to Dec 31 2025, illustrating how cash generation and usage have shifted across recent reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		0 0 0 (Dec 31 2024)
Operating Activities
Income-33.79
Depreciation & amortization0.00
Amortization of Other Assets0.04
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.00
Income (Loss) from Equity Method Investments-0.29
Financial Instruments and Foreign Currency Transaction13.25
Adjustments For Interest Expense-
Adjustments For Interest Income-
Adjustments For Sharebased Payments-
Adjustments For Net Investment In Sub Lease-
Adjustments For Decrease Increase In Trade And Other Receivables-
Adjustments For Decrease Increase In Prepaid Expenses-
Adjustments For Increase Decrease In Trade And Other Payables-
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Accounts Payable0.00
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-13.96
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.08
Discontinued operations0.00
Net Cash Flow from Investing Activities0.07
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net3.21
Other net14.52
Increase Decrease In Cash And Cash Equivalents-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities17.01
Effect of exchange rate on cash flow0.33
Discontinued operations0.00
Free Cash Flow-13.96
Total Cash Flow13.23
4 historic quarters locked

Sign in to unlock the full Nervgen Pharma cash flow history.

Sign In Create Free Account

About Nervgen Pharma Corp Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 40-F filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001104659-26-037357

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Get the full CSIMarket dataset: Subscribe API License